Actively Recruiting
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Led by Mayo Clinic · Updated on 2026-04-28
14
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
CONDITIONS
Official Title
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals with less than 34 weeks of gestation
- Individuals with severe preeclampsia or HELLP features
You will not qualify if you...
- Pregnant females with disseminated intravascular coagulopathy (DIC)
- Individuals with non-reassuring fetal status requiring delivery
- Individuals with non-viable fetuses
- Pregnancies less than 23 weeks gestation (previable)
- Individuals with stroke
- Individuals with in utero fetal demise
- Known atypical hemolytic uremic syndrome
- Familial or acquired thrombocytopenia purpura
- Paroxysmal nocturnal hemoglobinuria
- Allergy to ravulizumab
- Inability or unwillingness to sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic Minnesota
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
G
Gonzalez Suarez
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here